News
GSK showcases positive data with lung cancer drugs at WCLC
New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
Saturday 7 November 2026
